The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma

被引:236
作者
Del Castillo, Maria [1 ]
Romero, Fabian A. [2 ]
Arguello, Esther [2 ]
Kyi, Chrisann [3 ]
Postow, Michael A. [2 ]
Redelman-Sidi, Gil [2 ]
机构
[1] Jacobi Med Ctr, Dept Med, Bronx, NY USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
[3] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA
基金
美国国家卫生研究院;
关键词
infection; melanoma; checkpoint blockade; immunotherapy; ADVERSE EVENTS; NIVOLUMAB; IPILIMUMAB; DOCETAXEL; COLITIS;
D O I
10.1093/cid/ciw539
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The risk of infection among patients receiving immune checkpoint blockade is unknown. We retrospectively reviewed medical records of 740 patients with melanoma who received immune checkpoint blockers. Serious infection occurred in 54 patients (7.3%). The main risk factors were receipt of corticosteroids and/or infliximab.
引用
收藏
页码:1490 / 1493
页数:4
相关论文
共 24 条
[1]   PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].
Ansell, Stephen M. ;
Lesokhin, Alexander M. ;
Borrello, Ivan ;
Halwani, Ahmad ;
Scott, Emma C. ;
Gutierrez, Martin ;
Schuster, Stephen J. ;
Millenson, Michael M. ;
Cattry, Deepika ;
Freeman, Gordon J. ;
Rodig, Scott J. ;
Chapuy, Bjoern ;
Ligon, Azra H. ;
Zhu, Lili ;
Grosso, Joseph F. ;
Kim, Su Young ;
Timmerman, John M. ;
Shipp, Margaret A. ;
Armand, Philippe .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319
[2]   Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control [J].
Arriola, Edurne ;
Wheater, Matthew ;
Krishnan, Radhika ;
Smart, James ;
Foria, Vipul ;
Ottensmeier, Christian .
ONCOIMMUNOLOGY, 2015, 4 (10)
[3]   Prevention and Treatment of Cancer-Related Infections [J].
Baden, Lindsey Robert ;
Bensinger, William ;
Angarone, Michael ;
Casper, Corey ;
Dubberke, Erik R. ;
Freifeld, Alison G. ;
Garzon, Ramiro ;
Greene, John N. ;
Greer, John P. ;
Ito, James I. ;
Karp, Judith E. ;
Kaul, Daniel R. ;
King, Earl ;
Mackler, Emily ;
Marr, Kieren A. ;
Montoya, Jose G. ;
Morris-Engemann, Ashley ;
Pappas, Peter G. ;
Rolston, Ken ;
Segal, Brahm ;
Seo, Susan K. ;
Swaminathan, Sankar ;
Naganuma, Maoko ;
Shead, Dorothy A. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012, 10 (11) :1412-1445
[4]   Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].
Borghaei, H. ;
Paz-Ares, L. ;
Horn, L. ;
Spigel, D. R. ;
Steins, M. ;
Ready, N. E. ;
Chow, L. Q. ;
Vokes, E. E. ;
Felip, E. ;
Holgado, E. ;
Barlesi, F. ;
Kohlhaeufl, M. ;
Arrieta, O. ;
Burgio, M. A. ;
Fayette, J. ;
Lena, H. ;
Poddubskaya, E. ;
Gerber, D. E. ;
Gettinger, S. N. ;
Rudin, C. M. ;
Rizvi, N. ;
Crino, L. ;
Blumenschein, G. R. ;
Antonia, S. J. ;
Dorange, C. ;
Harbison, C. T. ;
Finckenstein, F. Graf ;
Brahmer, J. R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639
[5]   Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].
Brahmer, Julie ;
Reckamp, Karen L. ;
Baas, Paul ;
Crino, Lucio ;
Eberhardt, Wilfried E. E. ;
Poddubskaya, Elena ;
Antonia, Scott ;
Pluzanski, Adam ;
Vokes, Everett E. ;
Holgado, Esther ;
Waterhouse, David ;
Ready, Neal ;
Gainor, Justin ;
Aren Frontera, Osvaldo ;
Havel, Libor ;
Steins, Martin ;
Garassino, Marina C. ;
Aerts, Joachim G. ;
Domine, Manuel ;
Paz-Ares, Luis ;
Reck, Martin ;
Baudelet, Christine ;
Harbison, Christopher T. ;
Lestini, Brian ;
Spigel, David R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135
[6]  
Callahan MK, 2016, CANCER TREAT RES, V167, P231, DOI 10.1007/978-3-319-22539-5_9
[7]   Ipilimumab-induced colitis in patients with metastatic melanoma [J].
De Felice, Kara M. ;
Gupta, Arjun ;
Rakshit, Sagar ;
Khanna, Sahil ;
Kottschade, Lisa A. ;
Finnes, Heidi D. ;
Papadakis, Konstantinos A. ;
Loftus, Edward V., Jr. ;
Raffals, Laura E. ;
Markovic, Svetomir N. .
MELANOMA RESEARCH, 2015, 25 (04) :321-327
[8]   Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group [J].
De Pauw, Ben ;
Walsh, Thomas J. ;
Donnelly, J. Peter ;
Stevens, David A. ;
Edwards, John E. ;
Calandra, Thierry ;
Pappas, Peter G. ;
Maertens, Johan ;
Lortholary, Olivier ;
Kauffman, Carol A. ;
Denning, David W. ;
Patterson, Thomas F. ;
Maschmeyer, Georg ;
Bille, Jacques ;
Dismukes, William E. ;
Herbrecht, Raoul ;
Hope, William W. ;
Kibbler, Christopher C. ;
Kullberg, Bart Jan ;
Marr, Kieren A. ;
Munoz, Patricia ;
Odds, Frank C. ;
Perfect, John R. ;
Restrepo, Angela ;
Ruhnke, Markus ;
Segal, Brahm H. ;
Sobel, Jack D. ;
Sorrell, Tania C. ;
Viscoli, Claudio ;
Wingard, John R. ;
Zaoutis, Theoklis ;
Bennett, John E. .
CLINICAL INFECTIOUS DISEASES, 2008, 46 (12) :1813-1821
[9]   Improved Survival with Ipilimumab in Patients with Metastatic Melanoma [J].
Hodi, F. Stephen ;
O'Day, Steven J. ;
McDermott, David F. ;
Weber, Robert W. ;
Sosman, Jeffrey A. ;
Haanen, John B. ;
Gonzalez, Rene ;
Robert, Caroline ;
Schadendorf, Dirk ;
Hassel, Jessica C. ;
Akerley, Wallace ;
van den Eertwegh, Alfons J. M. ;
Lutzky, Jose ;
Lorigan, Paul ;
Vaubel, Julia M. ;
Linette, Gerald P. ;
Hogg, David ;
Ottensmeier, Christian H. ;
Lebbe, Celeste ;
Peschel, Christian ;
Quirt, Ian ;
Clark, Joseph I. ;
Wolchok, Jedd D. ;
Weber, Jeffrey S. ;
Tian, Jason ;
Yellin, Michael J. ;
Nichol, Geoffrey M. ;
Hoos, Axel ;
Urba, Walter J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (08) :711-723
[10]   Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center [J].
Horvat, Troy Z. ;
Adel, Nelly G. ;
Thu-Oanh Dung ;
Momtaz, Parisa ;
Postow, Michael A. ;
Callahan, Margaret K. ;
Carvajal, Richard D. ;
Dickson, Mark A. ;
D'Angelo, Sandra P. ;
Woo, Kaitlin M. ;
Panageas, Katherine S. ;
Wolchok, Jedd D. ;
Chapman, Paul B. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28) :3193-+